Latest News for: gyre

Edit

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

Nasdaq Globe Newswire 31 Mar 2025
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications ... .
Edit

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver ...

Nasdaq Globe Newswire 27 Mar 2025
Gyre Announces Publication of Protocol for Phase 3 Trial of F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology ... .
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Gyre Therapeutics Inc)

Public Technologies 25 Mar 2025
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue ... 2 ... GYRE THERAPEUTICS, INC. [GYRE] 5 ... C/O GYRE THERAPEUTICS, INC., 12770 HIGH BLUFF DRIVE, SUITE 150 3 ... C/O GYRE THERAPEUTICS, INC ... Gyre Therapeutics Inc.
Edit

Initial Registration Statement for Employee Benefit Plan (Form S-8) (Gyre Therapeutics Inc)

Public Technologies 20 Mar 2025
Gyre Therapeutics, Inc ... Gyre Therapeutics, Inc ... Gyre Therapeutics, Inc ... Gyre Therapeutics, Inc ... under the Gyre Therapeutics, Inc ... Gyre Therapeutics, Inc ... Gyre Therapeutics, Inc ... Gyre Therapeutics Inc.
Edit

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides

Enid News & Eagle 17 Mar 2025
Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 ... .
Edit

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K) (Gyre Therapeutics Inc)

Public Technologies 17 Mar 2025
Gyre Pharmaceuticals successfully advanced pirfenidone from research and development to commercialization in the PRC for the treatment of IPF ... Gyre Pharmaceuticals has completed a Phase 2 trial of F351 in the PRC for CHB-associated liver fibrosis.
  • 1
×